Why Moderna Stock Vaulted Higher Today
Shares of Moderna (NASDAQ: MRNA) were vaulting 9.3% higher as of 3:24 p.m. EST on Wednesday. The big gain came after the biotech announced interim data from an early stage clinical study evaluating its personalized cancer vaccine mRNA-4157 in combination with Merck's cancer immunotherapy Keytruda.
Moderna's interim results were from an expansion cohort of its ongoing phase 1 study that included 10 patients with HPV-negative head and neck squamous cell carcinoma (HNSCC) and 17 patients with micro-satellite stable colorectal cancer (MSS-CRC). Two of the HNSCC patients who received the mRNA-4157/Keytruda combo achieved a complete response with no cancer detected. Three other HNSCC patients achieved partial remission.
Image source: Getty Images.
Source Fool.com
